AppTech Payments (NASDAQ:APCX) reported $123.00 thousand in sales this quarter.
Pfizer Canada Announces LITFULO Receives Health Canada Approval, Becoming The First Approved Treatment For Severe Alopecia Areata In Canada
A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved for adults and adolescents over 12 years of age for treatment of severe alopecia areata.KIRKLAND, QC, Dec. 4, 2023 /CNW/ - Today, Pfizer Canada